GSK ends collaboration with IDEAYA for two candidates
Source: SeekingAlpha
2025-12-05 17:04:01 ET
More on IDEAYA Biosciences
- IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
- Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away
- IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2025 SMID Cap Biopharma Call Series Transcript
- Seeking Alpha’s Quant Rating on IDEAYA Biosciences
- Historical earnings data for IDEAYA Biosciences
Read the full article on Seeking Alpha
For further details see:
GSK ends collaboration with IDEAYA for two candidates
IDEAYA Biosciences Inc.
NASDAQ: IDYA
IDYA Trading
-3.25% G/L:
$32.77 Last:
100,573 Volume:
$34.03 Open:
IDYA Latest News
March 09, 2026 06:00:00 am
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
February 25, 2026 06:00:00 am
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
February 23, 2026 06:00:00 am
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
IDYA Stock Data
$2,916,661,394
85,474,748
1.71%
105
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
